Oncorus, Inc. (NASDAQ:ONCR – Get Rating) was the recipient of a large growth in short interest in April. As of April 30th, there was short interest totalling 1,030,000 shares, a growth of 31.9% from the April 15th total of 780,800 shares. Based on an average trading volume of 138,600 shares, the days-to-cover ratio is presently 7.4 days. Currently, 6.4% of the company’s stock are short sold.
Shares of NASDAQ:ONCR traded down $0.05 during midday trading on Wednesday, hitting $1.24. The stock had a trading volume of 874 shares, compared to its average volume of 131,717. The company has a market capitalization of $32.09 million, a PE ratio of -0.48 and a beta of 4.26. The stock has a 50 day moving average price of $1.48 and a two-hundred day moving average price of $3.69. Oncorus has a 1 year low of $1.03 and a 1 year high of $17.79.
Oncorus (NASDAQ:ONCR – Get Rating) last issued its earnings results on Wednesday, May 4th. The company reported ($0.69) earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.08. Equities analysts forecast that Oncorus will post -2.66 earnings per share for the current fiscal year.
Several research analysts have issued reports on the stock. Maxim Group lowered their price objective on shares of Oncorus from $20.00 to $7.00 in a research report on Thursday, March 10th. HC Wainwright assumed coverage on shares of Oncorus in a research report on Monday, March 28th. They set a “buy” rating and a $7.00 price objective on the stock. Finally, Zacks Investment Research raised shares of Oncorus from a “hold” rating to a “buy” rating and set a $1.25 price objective on the stock in a research report on Wednesday, May 11th.
About Oncorus (Get Rating)
Oncorus, Inc, a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers.
- Get a free copy of the StockNews.com research report on Oncorus (ONCR)
- Shoe Carnival’s Q1 Results Are No Joke, Shares Fall 15%
- Analog Devices Is Ready To Scale New Highs Despite Tech Wreck
- Dynatrace: Fundamentals are Positive While Being Punished
- Now’s The Time To Buy Disney (NYSE: DIS)
- 3 Small Caps With Big Return Potential
Receive News & Ratings for Oncorus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncorus and related companies with MarketBeat.com's FREE daily email newsletter.